MOLECULAR BASIS OF SKELETAL MUSCLE ATROPHY IN MYOTONIC DYSTROPHY by L.V. Renna
  
 
 
UNIVERSITÀ DEGLI STUDI DI MILANO 
Scuola di Dottorato in Scienze Biologiche e Molecolari 
XXVIII Ciclo 
 
 
 
MOLECULAR BASIS OF SKELETAL MUSCLE ATROPHY IN 
MYOTONIC DYSTROPHY 
 
 
 
 
L.V. RENNA 
PhD Thesis  
 
 
 
Scientific tutor: Prof. Roberto Colombo 
 
 
 
Academic year: 2014-2015 
 SSD: BIO/06 
 
 
Thesis performed at Department of Biosciences, University of Milan. 
 
 
 
  
Contents 
Part I 1 
1. Abstract 1 
2. State of the Art 2 
2.1 Myotonic Dystrophy 2 
2.2 Pathogenetic mechanism 6 
2.3 Skeletal muscle histopathology in DM1 and DM2 11 
2.4 Molecular pathways associated with skeletal muscle atrophy in DM1 
and DM2 
14 
3. Aim of the Project 19 
4. Main Results 21 
5. Conclusions and Future Prospects 25 
6. References 31 
Part II 49 
1. Content 49 
2. Overexpression of CUGBP1 in skeletal muscle from adult classic myotonic 
dystrophy  type 1 but not from myotonic dystrophy type 2 
50 
3. Progression of muscle histopathology but not of spliceopathy in 
myotonic dystrophy type 2 
62 
4. Premature senescence in primary muscle cultures of myotonic dystrophy 
type 2 is not associated with p16 induction 
74 
Part III 86 
Post insulin receptor signalling abnormalities in myotonic dystrophy skeletal 
muscle cells 
86 
1. Background and significance of the project 86 
2. Results and discussion 86 
2.1 Insulin receptor splicing and expression 87 
2.2 Glucose uptake 88 
2.3 Insulin signaling activation  90 
2.4 Cytoskeleton organization 91 
2.5 GLUT4 translocation 96 
3. Conclusions and future prospects 98 
4. References 99 
 
  
Abstract 
 
1 
 
Part I 
1. Abstract 
Myotonic dystrophy (DM) is an autosomal dominant multisystemic disorder characterized by a 
variety of multisystemic features including myotonia, muscular dystrophy, cardiac dysfunctions, 
cataracts and insulin-resistance. DM1 is caused by an expanded (CTG)n in the 3’ UTR of the 
DMPK gene, while DM2 is caused by the expansion of a (CCTG)n repeat in the intron 1 of the 
CNBP gene. In both forms, the mutant transcripts accumulate in nuclear foci altering the function of 
some alternative splicing regulators which are necessary for the physiological processing of 
mRNAs. However, the downstream pathways by which these RNA binding proteins cause skeletal 
muscle alteration are not well understood. For these reasons the aim of my PhD project was to 
analyze the molecular mechanisms behind DM skeletal muscle atrophy. In the first part of my PhD 
we have performed different studies to better define the molecular pathogenesis of DM. In 
particular, we have analysed the histopathological and biomolecular features of skeletal muscle 
biopsies from a cohort of DM1 and DM2 patients presenting different phenotypes. The results 
indicated that the splicing and muscle pathological alterations observed are related to the clinical 
DM1 and DM2 phenotype and that CUGBP1 seems to play a role only in DM1, confirming that the 
molecular pathomechanism of DM is more complex than the one actually suggested. These data 
were confirmed by the analysis of two different biopsies obtained from 5 DM2 patients that showed 
that morphological alterations evolve more rapidly over time than the molecular changes suggesting 
that the molecular mechanisms that drive to skeletal muscle atrophy are still unclear and that these 
features cannot be explained only by spliceopathy. For all these reasons we decided to analyse DM 
satellite cells activity in vitro. Satellite cells are the muscle fibre precursor cells and our data 
indicated that both DM1 and DM2 skeletal muscle cells have lower proliferative capability than 
control myoblasts. Moreover, the premature proliferative growth arrest observed in DM cells 
appears to be caused by an overexpression of p16  in DM1 muscle cells, while DM2 muscle cells 
stop dividing with telomeres shorter than controls, suggesting that in these cells the signaling 
involved in premature senescence depend on a telomere-driven pathway. Finally, we decided to 
analyze the insulin pathway which is involved in the regulation of skeletal muscle atrophy. Our data 
have shown that DM1 and DM2 cells exhibit a lower glucose uptake and a lower proteins activation 
after 10 nM insulin stimulation when compared to controls suggesting that also this pathway could 
play a role in the molecular mechanisms that drive skeletal muscle atrophy in DM patients. In 
conclusion, we have shown that the molecular mechanisms behind skeletal muscle atrophy in DM1 
and DM2 patients are more complicated than that previously suggested and further analysis are 
necessary to understand why skeletal muscle atrophy affect mainly type 1 fibres in DM1 patients, 
while on the contrary it affects selectively type 2 fibres in DM2 patients.  
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2. State of the Art 
2.1 Myotonic Dystrophy 
Myotonic dystrophy (DM) is an autosomal dominant multisystemic disorder characterized by a 
variety of multisystemic features including myotonia, muscular dystrophy, cerebral involvement, 
cardiac dysfunctions, cataracts and insulin-resistance (Mankodi and Thornton, 2002; Meola and 
Moxley, 2004). In 1909 Steinert and colleagues first described the first type of myotonic dystrophy 
(Myotonic Dystrophy type 1 or Steinert’s disease) that in 1992 was found to be caused by an 
expansion of an unstable CTG trinucleotide repeat in the 3’ untranslated region (UTR) of the 
myotonic dystrophy protein kinase gene (DMPK) which is located on chromosome 19q13.3 and 
codes for a myosin kinase expressed in skeletal muscle (Brook et al., 1992; Fu et al., 1992; 
Mahadevan et al., 1992). Subsequently, in 1994, a different multisystemic disorder was described 
and named myotonic dystrophy type 2 or proximal myotonic myopathy (PROMM). This type of 
DM was found to be caused by an unstable tetranucleotide repeat expansion, CCTG, in intron 1 of 
the nucleic acid-binding protein (CNBP) gene (previously known as zinc finger 9 protein gene, 
ZNF9) on chromosome 3q21 (Ricker et al., 1994; Liquori et al., 2001).  
A population-based genetic screen to determine the true frequency of DM has not yet been 
performed on a large scale (Thornton 2014). The most ambitious genetic screen to date showed a 
DM gene frequency of 1 in 1100 among Finnish blood donors, equally divided between DM1 and 
DM2 (Suominen et al., 2011). A referral center in England found that DM1 was the most common 
genetic neuromuscular disease, accounting for 29% of the population in a muscle clinic (Norwood 
et al., 2009). However, other studies estimates that DM1 prevalence in Europe ranges between 1 in 
8300 and 1 in 10700 (Magee et al., 1999; Siciliano et al., 2001). Regarding DM2, there are fewer 
epidemiologic studies of this disease if compared to DM1. The genetic diagnosis of DM1 and DM2 
was made with similar frequency at a reference laboratory in Germany, suggesting that the 
prevalence of the two disorders is similar in northern Europe (Udd et al., 2006). However in the 
United States clinical experience suggests that DM2 is 5-fold less common than DM1 (Thornton 
2014). 
Although DM1 and DM2 have similar symptoms, they also present a number of very dissimilar 
features making them clearly separate diseases (table 1). 
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Table 1: Comparison of clinical manifestation between DM1 and DM2 (Meola 2013). 
 
The spectrum of DM1 severity extends from lethal effects in infancy to mild, late-onset 
symptoms. Indeed, DM1 can be an adult-onset multisystem degenerative disorder but it also may 
affect fetal development and postnatal growth in individuals who carry large expansions. Indeed, 
patients with DM1 can be divided into four main categories: congenital, childhood-onset, adult-
onset and late-onset/asymptomatic (table 2).  
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Table 2: Summary of myotonic dystrophy type 1 phenotypes, clinical findings and CTG length 
(Meola 2013). 
 
 
Congenital DM1 (CDM) often presents before birth as polyhydramnios and reduced fetal 
movements. After delivery, the main features are severe generalized weakness, hypotonia and 
respiratory compromise that leads to a high mortality from respiratory failure. Surviving infants 
experience gradual improvement in motor function, since almost all CDM children are able to walk. 
Another characteristic feature of CDM is the delay in cognitive and motor development and all 
patients with CDM have learning difficulties and require special need schooling. Moreover, cerebral 
atrophy and ventricular enlargement are often present at birth (Spranger et al., 1997; Ashizawa  
1998). A progressive myopathy and the other main features of the adult classical form of DM1 can 
be develop in early adulthood in these patients (Joseph et al., 1997). The diagnosis of the DM1 
childhood onset form is often missed in affected adolescents or children because of uncharacteristic 
symptoms for a muscular dystrophy and apparently negative family history (Steyaert et al., 2000). 
The main features of classic adult-onset DM1 are distal muscle weakness, facial weakness and 
wasting. Moreover, these patients can develop cardiac dysfunctions such as conduction 
abnormalities with arrhythmia and conduction blocks contributing significantly to the mortality of 
the disease (Bassez et al., 2004; Chebel et al., 2005; Montella et al., 2005; Dello Russo et al., 2006). 
Another characteristic feature of adult DM1 is posterior subcapsular cataracts (Garrot et al., 2004). 
Finally, endocrine abnormalities are common in these patients and include testicular atrophy, 
hypotestosteronism, insulin resistance with usually mild type-2 diabetes (Meola 2000). In late-onset 
or asymptomatic DM1 patients myotonia, weakness and excessive daytime sleepiness are rarely 
present (Meola and Cardani, 2014).  
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In DM2 there are no distinct clinical subgroups although initially different phenotypes of DM2 
with proximal muscle weakness were described: DM2/Proximal Myotonic Myopathy (PROMM) 
and Proximal Myotonic Dystrophy (PDM) (Ricker et al., 1994; Thornton et al., 1994; Udd et al., 
1997). PROMM typically appears in adult life and has variable manifestations, such as early-onset 
cataracts (younger than 50 years), myotonia, muscle pain and weakness (Thornton et al., 1994; 
Ricker et al., 1995; Meola et al., 1996; Udd et al., 1997; Day et al., 1999; Ranum et al., 1998; 
Ashizawa et al., 2000; Meola 2000; Liquori et al., 2001; Moxley et al., 2002; Day et al., 2003; 
Schoser et al., 2004). Myotonia is often less apparent in DM2 compared with patients with DM1 
and, in cases of late-onset DM2, myotonia may only appear on electromyographic testing after 
examination of several muscles (Meola 2000). The cataracts in DM2 have an appearance identical 
to that observed in DM1, while cardiac problems appear to be less severe and frequent in patients 
with DM2 than in patients with DM1 (Meola et al., 2002; Flachenecker et al., 2003; Sansone et al., 
2013). The type of cognitive impairment that occurs in DM2 is similar but less severe than that of 
DM1. On the contrary, some endocrine dysfunction such as hypogonadism and glucose intolerance 
may also occur and worsen over time in DM2 (Thornton et al., 1994; Meola et al., 1999; Savkur et 
al., 2001; Day et al., 2003; Meola et al., 2003; Savkur et al., 2004). PDM patients show many 
features similar to those found in PROMM, including proximal muscle weakness, cataracts, and 
electrophysiologically detectable myotonia. However they present some features not present in 
PROMM, such as pronounced dystrophic–atrophic changes in the proximal muscles and late-onset 
progressive deafness (Udd et al., 1997).  
The most important discrepancy between DM1 and DM2 is absence of a congenital form in 
DM2 (Day et al., 2003; Udd et al., 2003). In patients affected by DM1 the repeat size range is from 
50 to 4000 CTG and is nearly always associated with symptomatic disease. Healthy individuals 
have between 5 and 37 CTG repeats while repeat lengths of 38–50 are considered premutation 
alleles, whereas 51–100 repeats are protomutations, both of which show increased instability toward 
expansion. Patients with premutations or protomutations are asymptomatic or present few mild 
symptoms, such as cataracts, but are at risk of having children with larger, pathologically expanded 
repeats (Thornton et al., 1994). The DM1 mutation length of 2000 repeats causes the congenital 
form of the disease (Ashizawa et al., 2000; Schoser et al., 2010). Since the size of the CTG repeat 
appears to increase over time in the same individual and across generation, children may inherit 
considerably longer CTG repeats than those present in the transmitting parent leading to a 
phenomenon known as genetic anticipation in which disease severity increases and/or age of onset 
of disease decreases from one generation to the next. However, the CTG repeat size does not always 
increase in successive generations of DM families. Intergenerational contraction of CTG repeats, a 
decrease in the CTG repeat size during transmission from parents to child, can also occur in about 
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6.4% of transmissions, most frequently during paternal transmissions (10%) (Ashizawa et al., 1994; 
Puymirat et al., 2009). In DM2, the size of the normal (CCTG)n expansion is below 30 repeats, 
while the range of expansion sizes in DM2 patients is huge (Bachinski et al., 2009). The smallest 
reported mutations vary between 55 and 75 CCTG and the largest expansions have been measured 
to be up about 11000 repeats (Liquori et al., 2001; Bachinski et al., 2009). The expanded DM2 
alleles show marked somatic instability, with significant increases in length over time (Liquori et 
al., 2001; Day et al., 2003). Since in DM2 the mutation usually contracts in the next generation 
being shorter in the children, this type of DM is not characterized by genetic anticipation and the 
presence of the congenital phenotype (Day et al., 2003; Udd et al., 2003). Moreover a large 
proportion of DM2 patients may be undiagnosed. Indeed, recent studies indicate that the co-
segregation of heterozygous recessive CLCN1 mutations in DM2 patients is higher than expected 
and modifies the DM2 phenotype (Suominen et al., 2008; Cardani et al., 2012). More recently, 
Bugiardini et al. have identified the first case of a DM2 patient with a concomitant mutation on 
SCN4A gene that codes for Nav1.4 voltage gate sodium channel (VGSC) expressed in muscle 
(Catterall et al., 2005; Bugiardini et al., 2015). Thus the CLCN1 or SCN4A mutations may 
contribute to exaggerating the DM2 phenotype and these patients could be more easily identified 
and diagnosed than DM2 patients without the modifier allele.  
 
2.2 Pathogenetic mechanism 
As described above, DM1 is caused by an expanded (CTG)n in the 3’ untranslated region of 
DMPK gene, while DM2 is caused by an expanded (CCTG)n in the intron 1 of CNBP gene (Brook 
et al., 1992; Fu et al., 1992; Mahadevan et al., 1992; Ricker et al., 1994; Liquori et al., 2001). 
Although genetically distinct, DM1 and DM2 share a common pathogenic mechanism. 
Experimental evidence supports a “RNA gain-of-function” mechanism in which expanded 
CUG/CCUG-containing transcripts accumulate in the cell nuclei as ribonuclear inclusions and are 
responsible for the pathologic features common to both disorders (figure 1). Indeed, the mutant 
RNAs form imperfect double-stranded structure which lead to the deregulation of several RNA 
binding factors, including the muscleblind‐like proteins (MBNLs), CUGBP1, hnRNP H and 
Staufen1 proteins (Timchenko et al., 1996; Philips et al., 1998; Miller et al., 2000; Kanadia et al., 
2003; Ho et al., 2004; Paul et al., 2006; Ravel-Chapuis et al., 2012). The MBNL proteins appear to 
play a prominent role in DM pathogenesis since each of the three MBNL isoforms (MBNL1, 
MBNL2 and MBNL3) are sequestered by CUG RNAs in the cell nuclei (Miller et al., 2000; Faradei 
et al., 2002). Moreover Mbnl1 and Mbnl2 knockout mice recapitulate multiple features of adult-
onset DM (Kanadia et al., 2003, 2003). Interestingly, while Mbnl1 knockout mice develop the 
muscle, eye, and RNA splicing abnormalities that are characteristic of DM1 disease and show 
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modest effects on alternative splicing regulation in the brain, the loss of Mbnl2 leads to widespread 
changes in postnatal splicing patterns in the brain but not in skeletal muscle (Kanadia et al., 2003; 
Suenaga et al., 2012). Even if nothing is known about the functions of MBNL3 in vivo, in vitro 
studies show that MBNL3 acts as an antagonist of myogenesis possibly by maintaining myoblasts 
in a proliferative state. Moreover Mbnl3 isoform knockout mice show age-dependent impairment of 
adult muscle regeneration suggesting that Mbnl3 inhibition by toxic RNA expression may be a 
contributing factor to the progressive skeletal muscle weakness and wasting characteristic of DM 
(Squillace et al., 2002; Lee et al., 2008; Poulos et al., 2013). CUGBP1, a member of the family of 
CELF (CUGBP, Elav-like family) proteins, is a regulator of alternative splicing and of mRNA 
translation and stability (Timchenko et al., 2005; Barreau et al., 2006; Huichalaf et al., 2009, 2010; 
Lee et al., 2010). CUGBP1 does not colocalize with ribonuclear foci in DM1 cells, however this 
protein was found to be overexpressed in DM1 myoblasts, skeletal muscle and heart tissues due to 
PKC-mediated hyperphosphorylation and subsequent protein stabilization and upregulation 
(Timchenko et al., 1996; Miller et al., 2000; Savkur et al., 2001; Fardaei et al., 2002; Mankodi et al., 
2003; Dansithong et al., 2005; Kuyumcu-Martinez et al., 2007). On the contrary the role of 
CUGBP1 in DM2 is particularly intriguing with contradictory results being reported. Timchenko 
and colleagues reported an increase of CUGBP1 in DM2 cultured myoblasts and muscle biopsies 
analyzing cytoplasmic extracts. Moreover they reported that expression of pure RNA CCUG 
repeats in normal human myoblasts, in C2C12 cells and in a DM2 mouse model also increased 
levels of CUGBP1 (Salisbury et al., 2009). On the contrary, in two different reports, the analysis of 
total cellular extract from DM2 cultured myoblasts and from muscle biopsies of DM2 patients did 
not show differences in CUGBP1 levels (Lin et al., 2006; Pelletier et al., 2009). Other splicing 
factors involved in early phases of pre-mRNA processing have been found to be altered in DM 
pathologies confirming that a general alteration of pre-mRNA processing could be at the basis of 
DM phenotype. Indeed an elevation of the steady-state level of hnRNPH has been observed in both 
DM1 and DM2 myoblasts (Fakan 1994; Paul et al., 2006; Perdoni et al., 2009). Staufen1 is another 
alternative splicing regulator that has been found to be increased in skeletal muscle from DM1 
mouse models and patients. Interestingly, Staufen1 up-regulation might have a protective role in the 
DM1 pathology since it appears that the increase in Staufen1 may be a compensatory mechanism 
used by muscle fibres to reduce and/or delay the pathologic effects caused by MBNL1 sequestration 
and CUGBP1 up-regulation (Ravel-Chapuis et al., 2012). Thus, the misregulation of alternative 
splicing clearly plays a central role in the development of important DM symptoms. Indeed , among 
the symptoms of DM, myotonia, insulin resistance and cardiac problems seem to be correlated with 
the disruption of the alternative splicing of some specific proteins. Indeed, it has been reported that 
an alteration in the insulin receptor (IR) splicing can lead to insulin insensitivity and a 
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predisposition to diabetes, an alteration in the muscle chloride channel (CLCN1) can lead to 
myotonia, while an alteration in skeletal muscle calcium ATPase SERCA may contribute to the 
Ca
2+
 homeostasis impairment that characterise DM muscle cells (Savkur et al., 2001; 2004; Kimura 
et al., 2005).  
 
 
Figure 1: “RNA gain of function” model in DM1 and DM2 (Wheeler 2008). 
 
However, there is no direct evidence of a cause–effect relationship between symptoms and 
missplicing and it seems that spliceopathy may not fully explain the multisystemic disease 
spectrum. Indeed, Bachinski and collaborators performed global array-based expression and 
splicing profiling on a large number of DM and non-DM neuromuscular patients and found that 
DM1 and DM2 skeletal muscles were essentially identical to each other for both expression and 
splicing. Moreover the authors found no evidence for widespread missplicing as a DM-specific 
pathomechanism in skeletal muscle since most expression and splicing changes were shared 
between multiple muscular dystrophies, as previously suggested (Bachinski et al., 2010; 2014; 
Orengo et al., 2011). This evidence suggests that splicing changes may be a much more general 
phenomenon of muscle disease and can be secondary to muscle regeneration (Bachinski et al., 
2010; Orengo et al., 2011). All these studies strongly suggest that DM molecular pathogenesis may 
be more complex involving changes in gene expression and translation efficiency, non-conventional 
translation and micro-RNA (miRNA) deregulation (figure 2). The effects of repeat expansion on 
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gene expression were revealed by microarray analysis of DM1 and DM2 muscle biopsies and 
confirmed by the mRNA profiling of transgenic mice expressing non-coding CUG repeats in 
skeletal muscle (Botta et al., 2007). Interestingly, most of the changes detected were also found in 
Mbnl1 knock-out mice, indicating that transcriptional deregulation results partially from MBNL1 
loss of function (Osborne et al., 2009). Altered gene expression may also result from a direct effect 
of the repeat expansion on transcription factors. Indeed, expanded DMPK transcripts bind SP1 and 
RARγ in DM1 myocytes, reducing their availability and the expression of target transcripts 
(Ebralidze et al., 2004). Moreover NKX2-5 upregulation in DM1 skeletal muscle and heart affects 
the expression of downstream genes, possibly contributing to the muscle regenerative defects and 
cardiac conduction abnormalities (Yadava et al., 2008). The mislocalization of SHARP 
(SMART/HDAC1- associated repressor protein) in the cytoplasm in DM1 myoblasts may alter the 
steady-state levels of a set of RNA transcripts implicated in muscle development and function 
(Dansithong et al., 2011). The absence of co-localization of transcription factors with CUG-
containing nuclear foci does not exclude a pathogenic role. Indeed, a fraction of expanded DMPK 
transcripts does not aggregate and remains soluble in DM1 cells, interacting with splicing regulators 
and transcription factors and thus contributing to pathology (Junghans 2009). A novel molecular 
mechanism that may contribute to the pathogenesis of myotonic dystrophies has been described by 
Ranum's group (Zu et al., 2013). RNA transcripts containing expanded CAG repeats can be 
translated in the absence of a starting ATG and this non-canonical translation, called Repeat 
Associated Non-ATG translation (RAN-translation) occurs across expanded CAG repeats in all 
reading frames (CAG, AGC, and GCA) to produce homopolymeric proteins of long polyglutamine, 
polyserine, and polyalanine tracts. RAN translation across human spinocerebellar ataxia type 8 
(SCA8) and myotonic dystrophy type 1 (DM1) CAG expansion transcripts results in the 
accumulation of SCA8 polyalanine and DM1 polyglutamine expansion proteins in SCA8 and DM1 
mouse models and human tissue (Zu et al., 2011). Antibodies developed specifically against DM1 
polyGln proteins, detect polyGln nuclear aggregates in DM1 mouse tissues and DM1 patient 
cardiac myocytes, leukocytes, and myoblasts not detectable in control tissues. RAN-translation 
products appear to be toxic to cells and may contribute to DM1 pathology. More recently RAN 
translation has been found to occur across intronic DM2 CCUG transcripts and that these transcripts 
produce a tetra-repeat expansion protein with a repeating Leu-Pro-Ala-Cys (LPAC) motif. 
Moreover, an LPAC antibody shows strong immunostaining in human DM2 autopsy brain but not 
in controls. Immunostaining has been observed in neurons, astrocytes and glia in frontal cortex, 
hippocampus and basal ganglia. These data suggest that RAN translation may be common to both 
DM1 and DM2 and that RAN proteins may be responsible for some of the CNS features of DM (Zu 
et al., 2013). miRNAs are small non-coding RNA modulating gene expression at posttranscriptional 
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level and their expression and intracellular distribution are deregulated in many human diseases, 
including muscular dystrophies (Eisenberg et al., 2009; Greco et al., 2009, 2012; Gambardella et al., 
2010; Perbellini et al., 2011). Both in DM1 and DM2 it has been demonstrated that the highly 
regulated pathways of miRNA is altered in skeletal muscle potentially contributing to DM 
pathogenetic mechanisms (Gambardella et al., 2010; Perbellini et al., 2011; Greco et al., 2012). 
Interestingly, miR-1 downregulation in DM1 and DM2 hearts is mediated by the functional 
depletion of MBNL1, which affects the misprocessing of pre-miR-1 (Rau et al., 2011 ). Whether 
MBNL1 regulates the processing of other miRNAs remains to be determined. DM-associated 
miRNA deregulation alters the expression of target transcripts, possibly contributing to disease 
pathology (Perbellini et al., 2011; Rau et al., 2011). Interestingly, Perfetti et al. identify a signature 
of miRNA deregulated in peripheral blood plasma from DM1 patients . In particular one specific 
miRNA, miR-133a, clearly correlates with muscle strength measurement and increased in patients 
with higher MIRS score, potentially reflecting disease severity (Perfetti et al., 2014).  Finally, in 
DM1 cells, CUG-containing RNAs form imperfect hairpin structures, which can be cleaved by the 
RNA interference (RNAi) machinery to generate CUG-containing small interference RNAs 
(siRNAs) that are capable of binding complementary sequences in target mRNAs, possibly 
interfering with their expression and contributing to disease pathogenesis (Krol et al., 2007).  
The understanding of DM pathogenetic mechanism is improving fast, nevertheless there are 
some key aspects of the disease that deserve further investigation. Indeed the neurological 
manifestations of DM, the differences between DM1 and DM2 clinical features such as the 
presence of a congenital phenotype in DM1 and histopatholgical alterations in skeletal muscle does 
not still have a definitive molecular explanation.   
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Figure 2: Molecular pathogenesis of DM1: mechanisms of RNA toxicity, spliceopathy, 
deregulation of gene expression and proteotoxicity (Sicot et al., 2011). 
 
2.3. Skeletal muscle histopathology in DM1 and DM2  
The histological features of skeletal muscle biopsy in DM1 and DM2 are very similar, and 
sufficiently characteristic that a diagnosis of DM can be suggested based on muscle biopsy alone 
(table 3) (Day et al., 2003; Schoser et al., 2004).  
 
Table 3: Muscle histopathology in DM1 and DM2. +++ present in >75% of biopsies; ++ present in 
20-50% of biopsies; + present in 10-24% of biopsies; ± occasionally present; - absent (Meola 
2013). 
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In both diseases, affected muscles present an increase in the number of central nuclei and a 
high variability in fibres diameters that commonly ranges from less than 10 μm to greater than 100 
μm. Moreover, in both disease, basophilic regenerating fibres, splitting fibres, fibrosis and adipose 
deposition can occur in relation to the extent of muscle involvement. Ring finger fibres and 
sarcoplasmic masses are generally more frequent in DM1 muscle biopsy. However, the comparison 
of muscle biopsy findings in classic DM1 with those in DM2 has indicated that specific features are 
present in both diseases. The presence of severely atrophic fibres with pyknotic nuclear clumps are 
frequently found in DM2 biopsies also before the occurrence of muscle weakness, while on the 
contrary in DM1 this feature is present only in end-stage muscle biopsy (Vihola et al., 2010). 
Moreover, a predominant type 2 fibre atrophy in DM2 muscle biopsies has been described, while on 
the contrary in DM1 biopsies fibre atrophy seems to affect mainly type 1 fibres (Vihola et al., 2003; 
Schoser et al., 2004; Bassez et al., 2008; Pisani et al., 2008). In DM2 muscle biopsy central 
nucleation selectively affects type 2 fibres and the atrophic nuclear clumps express fast myosin 
isoform (type 2 fibre) indicating that DM2 is predominantly a disease of type 2 myofibres (Bassez 
et al., 2008) (figure 3).  
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Figure 3: Panel showing muscle histology in DM1 and DM2. A) Hematoxylin & Eosin stained 
transversal sections of DM1 muscle biopsy presenting a severe fibrosis, fibre size variation (arrow) 
and central nuclei (asterisk). B) Hematoxylin & Eosin stained transversal sections of DM2 muscle 
biopsy with fibre size variation, central nuclei and nuclear clump (arrowhead). C) Slow myosin 
(MHCslow) stained section of DM1 muscle biopsy. The population of atrophic fibres (dark brown) 
is preferentially type 1 fibres (arrows). D) Fast myosin (MHCFast) stained section of DM1 muscle 
biopsy. Type 2 fibres (dark brown) are predominantly affected in DM2 muscle. E-G) Fluorescence 
in situ hybridization (FISH) (E, red spots) in combination with MBNL1-immunofluorescence (F, 
green sposts) on DM2 muscle biopsy. (Meola and Cardani, 2014). 
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2.4 Molecular pathways associated with skeletal muscle atrophy in DM1 and DM2 
To date there are no definitive explanations for the histopathological alterations observed in 
DM skeletal muscle.  
Since the discover of the DM1 genetic locus, several mouse models have been generated for 
examination of the molecular basis of DM1 histopathology. DM1 mouse models designed to study 
DM1 muscle pathology can be divided in two different groups: the first group addresses the role of 
the accumulation of long CUG, while the second group includes models designed to elucidate the 
role of the RNA binding proteins CUGBP1 and MBNL1 (Mankodi et al., 2000; Seznec et al., 2001; 
Kanadia et al., 2003; Timchenkoet al., 2004; Ho et al., 2005;  Orengoet al., 2008; Ward et al., 
2010). The first transgenic mouse model that demonstrated the crucial role of CUG RNA in DM1 
muscle pathology expressed 250 CUG repeats in the 3’-UTR of skeletal muscle actin gene (HSALR 
mice) (Mankodi et al., 2000). These mice developed myotonia and skeletal muscle myopathy 
similar to the muscle histopathology observed in DM1 patients. Indeed, skeletal muscles of these 
mice showed an increase in the number of central nuclei and variability in fibres size. However, 
initial studies did not reveal overt muscle atrophy in adult HSA
LR
 mice, while recent analysis 
showed that the total number of myofibres is reduced in gastrocnemius of six-month-old mice in at 
least some mouse lines of this model (Mankodi et al., 2000; Jones et al., 2012). A similar effect of 
mutant CUG repeats on muscle pathology was observed in a DM1 mouse model that expresses the 
entire human DMPK gene containing 300 expanded CTG repeats (DM300 mice) (Seznec et al., 
2001). Also these mice developed myotonia and skeletal muscle myopathy similar to the one 
observed in DM1 patients with central nuclei, increased variability in fibre size and focal areas of 
regeration-degeneration that express the neonatal myosin heavy chain. Moreover, skeletal muscles 
of these mice show an increased number of atrophic fibres with specific atrophy of type 1 fibres and 
whole body weight was reduced even at a young age (Seznec et al., 2001). The same mice with a 
bigger CTG expansion (550 CTG, DM550) developed progressive age-dependent muscle weakness 
and wasting associated with reduced muscle mass and fibre diameter (Vignaud et al., 2010). The 
worst effect of mutant CUG repeats on muscle pathology was observed in the DM1 inducible 
mouse model expressing a mutant 3’-UTR of DMPK containing a 960 CUG repeats under the 
control of a skeletal muscle promoter. These mice were characterised by a severe muscle wasting 
that reduced muscle size. Moreover, skeletal muscles of these mice show an increase in small sized 
fibres, fibrosis, myofibre degeneration, and a reduction in performance on the treadmill (Orengo et 
al., 2008). The analyses of these DM1 mouse models clearly show that muscle wasting in DM1 is 
caused by CTG repeats, but however a high variability dependent on the length of CTG expansions 
and the genomic environment of CTG repeats was observed. Although it is well established that 
expanded CUG repeats are responsible for the myofibre loss in DM1, the downstream pathways by 
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which the mutant CUG repeats cause muscle wasting are not well understood. Since it’s known that 
the mutant CUG repeats misregulate mainly two RNA-binding proteins, CUGBP1 and MBNL1, 
abnormal functioning of these proteins could cause muscle atrophy in DM1 (Milleret al., 2000; 
Philips et al., 1998; Timchenko et al., 1996). Indeed, mouse models with increased expression of 
CUGBP1 revealed the crucial role of this protein in muscle development and function. Elevation of 
CUGBP1 expression in traditional transgenic mouse models interferes with muscle development, 
causing a delay in myogenesis consistent with the muscle abnormalities observed in congenital 
DM1 patients (Ho et al., 2005; Timchenko et al., 2004). The muscle of mice with deleted MBNL1 
shows myotonia, split fibres, and an increase in central nuclei (Kanadia et al., 2003). MBNL1 and 
CUGBP1 are not only two splicing regulators. Indeed, recent reports showed that MBNL1 is also 
involved in control of destabilization of some mRNAs, in miR-1 processing, and in regulating 
localization of mRNAs (Rau et al., 2011; Masuda et al., 2012; Wang et al., 2012). CUGBP1 is a 
multifunctional protein that functions in the nuclei and cytoplasm and regulates splicing, stability, 
and translation of RNAs (Charlet et al., 2002; Lee et al.,2010; Moraes et al., 2006; Paillard et al., 
1998; Savkur et al., 2001;Timchenko et al., 2005, 2006; Vlasova et al., 2008; Zhang et al.,2008). 
MBNL1 and CUGBP1 have antagonistic splicing activities, and their activity is crucial for the 
regulation of spliced isoforms during normal skeletal muscle and heart development (Ranum and 
Cooper, 2006). In DM1, a reduction in MBNL1 splicing activity and increase in CUGBP1 splicing 
activity results in accumulation of embryonic-specific transcripts and their protein products in adult 
muscle, affecting muscle function and leading to muscle atrophy. Indeed, several mRNAs that play 
a critical role in normal muscle function show abnormal splicing patterns in DM1, including 
mRNAs encoding a skeletal muscle chloride ion channel 1 (Clcn1), sarcoplasmic/endoplasmic 
reticulum Ca
2+
ATP-ase (SERCA1), a protein localized to the Z line (Cipher), a protein involved in 
the T-tubule formation (BIN1), Ca
2+ 
release channel or Ryanodine Receptor 1 (RyR1), and L-type 
Ca
2+
channel and voltage sensor (Cav1.1) (Charlet et al.,2002; Mankodi et al., 2002; Kimura et al., 
2005; Kanadia et al., 2006; Fugier et al., 2011; Tang et al.,2012). Missregulation of SERCA1 and 
RyR1 in DM1 might affect Ca
2+ 
homeostasis, leading to the activation of Ca
2+
-dependent proteases 
such as calpain and causing muscle atrophy. Abnormalities of BIN1 splicing might disrupt 
formation of T-tubules resulting in muscle under-development and weakness. The Cav1.1 channel 
plays a crucial role in the regulation of excitation–contraction coupling (Tanget al., 2002). Even if 
comparison of splicing patterns in the muscle of HSA
LR
 mice with those in mice with deleted 
MBNL1 shows similar splicing abnormalities, MBNL1 knock out mice do not show evident muscle 
wasting suggesting that other members of MBNL family (MBNL2 or MBNL3) might compensate 
for the lack of MBNL1 (Osborne et al., 2009, Kanadia et al., 2003). However, a critical difference 
between MBNL1 KO mice and CUG inducible mice is that the MBNL1 KO mice have normal 
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levels of CUGBP1, whereas CUGBP1 expression is elevated in the inducible DM1 model 
suggesting that the elevated CUGBP1 could be responsible for muscle wasting in DM1 mouse 
models (Orengo et al., 2008). Indeed, the analysis of alternative splicing pattern show that in the 
inducible CUG mouse model present several mRNAs that are mispliced but that have a normal 
splicing pattern in MBNL1 KO mice. These mRNAs include those encoding Ankyrin 2 (Ank2), F 
actin capping protein beta subunit (Capzb), and fragile X mental retardation syndrome-associated 
protein (Fxr1) (Orengoet al., 2008). Ank2 mediates binding of membrane proteins to the 
cytoskeleton and Capzb is associated with filament growth. Fxr1 is a member of the fragile X 
family of RNA-binding proteins that regulate RNA processing on several levels and its deletion in 
mice causes muscle loss suggesting that its alteration in DM1 cells could reduce proteins synthesis 
in DM1 cells leading to skeletal muscle atrophy (Mientjes et al., 2004; Whitman et al., 2011). In 
agreement with this suggestion, the CUGBP1 mouse model developed myofibre atrophy 
accompanied by a reduction in the weight, increased inflammatory infiltrates and fibre degeneration 
(Ward et al., 2010). Although mice with elevated CUGBP1 expression develop muscle atrophy, the 
contribution of the splicing activity of CUGBP1 to this feature of the disease remains to be 
determined. A recent study using a mouse model that expresses a nuclear dominant-negative form 
of CUGBP1 showed that these mice have disrupted splicing without muscle atrophy, suggesting 
that abnormal cytoplasmic functions of CUGBP1 might contribute to muscle atrophy in DM1 
(Berger et al., 2011). Indeed, in DM1 muscles an increase in the expression of CUGBP1 un-
phosphorylated at Ser302 could repress protein translation in stress granules (SGs) leading to 
muscle wasting (Huichalaf et al., 2010). It has been observed that expanded CUG repeats reduce 
phosphorylation of Ser302 through a reduction in cyclin D3 due to elevated levels of active GSK3β 
kinase (Salisbury et al., 2008; Jones et al., 2012). Interestingly the inhibition of GSK3β in HSALR 
mice corrected CUGBP1 translational activity and increased the number of the activate myogenic 
satellite cells (Jones et al., 2012). Satellite cells are the skeletal muscle precursor cells and provide 
the potential for both pre and post-natal growth of skeletal muscle and for its regeneration following 
injury (Bischoff et al., 1994; Relaix et al., 2012). In normal muscles, satellite cells are quiescently 
located between the sarcolemma and the basal lamina of mature myofibres and following injury 
they become activated and then proliferate and fuse into myotubes to regenerate or repair muscle 
fibres (Cooper et al., 1999; Renault et al., 2002). It is known that the regenerative capacity of 
skeletal muscle depends on the number of progenitor cells which declines with age in humans and 
on their activation, proliferation and differentiation potential (Bodnar et al., 1998; Renault et al., 
2002; Wright et al., 2002). The proliferative potential of human satellite cells decreases during 
postnatal  muscle growth due to the replicative senescence that could affect both the regeneration 
process and the maintenance of muscle mass, since the differentiation program of senescent 
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myogenic precursor cells would become defective due to impaired myogenesis (Renault et al., 
2002; Wright et al., 2002). Indeed, Bigot et al. (2008) observed that senescent myoblasts are still 
able to fuse and form myotubes, yet significantly smaller and with a significant reduction in the 
number of nuclei per myotube and in the fusion index, compared with those obtained from young 
myoblasts (Bigot et al., 2008). In a recent report, it has been demonstrated that satellite cells 
isolated from DM1 patients reached the proliferative senescence when their mean telomere lengths 
were longer than those observed in passage-matched control cells indicating that DM1 cells reach 
proliferative arrest prematurely, independently of telomere shortening (Thornell et al., 2009). It 
appears that the treatment with GSK3 inhibitors in 6-month-old HSA
LR
 mice increase the number of 
myogenic satellite cells that is accompanied by the reduction of muscle histopathology and 
improvement of the grip strength (Jones et al.,2012). However the pathways by which GSK3 
inhibitors increase the number of activated satellite cells are still not known.  
In contrast to DM1, less is known about the molecular mechanisms that induce muscle atrophy 
in DM2. Indeed the role of MBNL1 and CUGBP1 in muscle atrophy in DM2 has been poorly 
investigated. Since it is known that CCUG repeat expansions in DM2 are longer than CUG 
expansions in DM1, it is expected that DM2 expansions will have a greater inhibitory effect on 
MBNL1 splicing (Mankodi et al., 2001). However, muscle atrophy in DM2 muscle is milder than 
that in DM1, suggesting that MBNL1 sequestration and a reduction of MBNL1 splicing activity in 
DM2 cells might play only a partial role in DM2 muscle atrophy. Also the contribution of CUGBP1 
to DM2 requires additional investigation because, as mentioned above, contradictory results about 
its expression has been reported (Lin et al., 2006; Pelletier et al., 2009; Salisbury et al., 2009). 
Comparison of DM1 and DM2 myoblast cell culture models showed that levels of active CUGBP1-
eIF2 complexes are reduced during differentiation of DM1 myoblasts, whereas the amounts of these 
complexes are normal in DM2 myotubes suggesting that the regulation of CUGBP1 activity in 
DM1 and DM2 muscles might be different (Schoser and Timchenko, 2010). Since the discover of 
the DM2 genetic locus, several studies have been performed to define the possible role of 
ZNF9/CNBP protein in muscle atrophy and weakness in DM2. Indeed, ZNF9/CNBP plays a key 
role in the translational control of mRNAs containing 5’-terminal oligopyrimidine (5’TOP) tracts 
that encode proteins of the translational apparatus including ribosomal proteins and elongation 
factors (Pellizzoni et al., 1997;Huichalaf et al., 2009; Meyuhas, 2000). DM2 muscle biopsies have 
shown reduced levels of several TOP proteins leading to a reduction in the rate of global protein 
synthesis, which might explain the muscle atrophy in DM2 (Huichalaf et al., 2009). The role of 
ZNF9/CNBP in muscle atrophy is supported by the muscle phenotype in ZNF9 KO mice, which 
includes fibre size variability and weakness similar to those observed in DM2 patients (Chen et al., 
2007). Two recent reports showed that ZNF9/CNBP levels are reduced in DM2 muscle biopsies, 
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although other authors reported that some DM2 patients have normal levels of this proteins (Botta 
et al., 2006; Salisbury et al.,2009; Raheem et al., 2010). It is known that muscle atrophy can occur 
due to a misbalance between protein synthesis and protein degradation and interestingly it has been 
shown that proteasome activity in DM2 muscle cells is affected, possibly as a result of the binding 
of RNA CCUG repeats to multiprotein complexes containing the 20S proteasome (Salisbury et al., 
2009). Proteomic analysis of DM2 myotubes indicated that these cells have an alteration in the 
ubiquitin proteasome system that suggests an increase in proteasomal activity in DM2 myotubes 
that leads to a dysfunction of protein degradation (Rusconi et al., 2010). 
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3. Aim of the Project 
Myotonic dystrophy (DM) is an autosomal dominant multisystemic disorder characterized by a 
variety of multisystemic features including myotonia, muscular dystrophy, cerebral involvement, 
cardiac dysfunctions, cataracts and insulin-resistance (Mankodi and Thornton, 2002; Meola and 
Moxley, 2004). Myotonic dystrophy type 1 (DM1) is caused by an expanded (CTG)n in the 3’ 
untranslated region of DMPK gene, while a second form (DM2) is caused by an expanded (CCTG)n 
in the intron 1 of CNBP gene (Brook et al., 1992; Fu et al., 1992; Mahadevan et al., 1992; Ricker et 
al., 1994; Liquori et al., 2001). In both forms, the CUG- and CCUG- containing transcripts 
accumulate in nuclear foci altering the function of the specific alternative splicing regulators, 
CUGBP1 and MBNL1, which are necessary for the physiological processing of mRNAs. These 
alterations lead to aberrant alternative splicing of different genes that explain different DM features 
(Taneja et al., 1995; Philips et al., 1998; Michalowski et al., 1999; Timchenko et al., 2001; Mankodi 
et al., 2001; Ranum and Day, 2004; Day and Ranum, 2005). However, the downstream pathways by 
which these RNA binding proteins cause skeletal muscle alteration such as the presence of very 
atrophic fibres, variability of myofibre size, ring fibres, and an increase in the number of fibres with 
central nuclei are not well understood (Meola 2000; Day and Ranum, 2005). For these reasons the 
general aim of this project was to understand the molecular mechanisms behind DM skeletal muscle 
alterations, focusing in particular on muscle atrophy.  
In particular, we decided to study the molecular basis of skeletal muscle atrophy through the 
analysis of three different mechanisms potentially involved in this feature of myotonic dystrophy: 
 The role of CUGBP1 and ZNF9/CNBP. Indeed, even if current evidence suggests that 
mutant CUG and CCUG repeats are responsible for muscle atrophy in DM1 and DM2, 
additional studies are needed to determine the contribution of the splicing regulators 
MBNL1 and CUGBP1 to the development of skeletal muscle alterations. Moreover, in DM2 
patients the role of ZNF9/CNBP expression is still controversial and requires additional 
investigation since some DM2 patients show reduced protein levels but others do not (Botta 
et al., 2006; Margolis et al., 2006; Huichalaf et al., 2009; Pelletier et al., 2009; Raheem et 
al., 2010).  
 The role of satellite cells. Indeed, it has been demonstrated that satellite cells isolated from 
DM1 patients reached the proliferative senescence when their mean telomere lengths were 
longer than those observed in passage-matched control cells indicating that DM1 cells reach 
proliferative arrest prematurely, potentially leading to skeletal muscle atrophy (Thornell et 
al., 2009). However, even if a recent study have shown that DM2 myoblasts exhibit 
senescence related features when cultured at early passages, additional studies are needed to 
elucidate if DM2 satellite cells activity is impaired as reported for DM1 possibly leading to 
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skeletal muscle atrophy.  
 The role of insulin/IGF1 pathway. Indeed, it is known that this pathway promotes the 
synthesis and inhibits the degradation of muscle specific proteins and muscle atrophy can 
occur due to a misbalance between protein synthesis and protein degradation. Even if 
preliminary studies have shown that DM2 muscle cells show an alteration in proteins 
degradation system, other studies are necessary to better define the molecular alterations of 
the insulin/IGF1 pathway in both DM1 and DM2 patients (Rusconi et al., 2010).  
The results will potentially lead to the identification of novel biomarkers that could be target for 
therapeutic intervention. Developing therapies for the prevention and treatment of muscle atrophy 
process will enhance the quality of life of patients who suffer from myotonic dystrophy and it 
would be beneficial to society as a whole since it would lead to a reduction in economic and 
productivity burdens associated with skeletal muscle damage. 
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4. Main Results 
 
This project has been performed both ex vivo on biceps brachii human biopsies from control and 
DM patients and in vitro on myoblasts and myotubes cultures obtained from human control and DM 
biopsies. 
In the first part of my PhD we have performed different studies to better define the molecular 
pathogenesis of DM. Indeed, even if it’s known that the common key feature of DM pathogenesis is 
the nuclear accumulation of mutant RNA that causes the alteration in the activity of two RNA 
binding proteins, MBNL1 and CUGBP1, DM1 and DM2 show disease-specific features that make 
them separate diseases suggesting that other cellular and molecular pathways may be involved. In 
this background, we have analyzed the histopathological and biomolecular features of skeletal 
muscle biopsies from a cohort of DM1 and DM2 patients in relation to different phenotypes. On the 
basis of clinical phenotype, DM1 cohort has been divided in three phenotypes (5 patients with mild 
phenotype E1, 10 patients with classic phenotype E2 and 3 adult patients with Congenital Myotonic 
Dystrophy phenotype CDM). The DM2 cohort included 5 patients with a paucisymptomatic (PS) 
phenotype, 5 patients with Proximal Myotonic Dystrophy (PDM) phenotype and 10 patients with 
Proximal Myotonic Myopathy (PROMM). The histopathological analysis of muscle sections has 
shown that there is a positive correlation between the skeletal muscle impairment and the clinical 
phenotype. Indeed, the most severe histopathological alterations such as an increase in the atrophy 
and hypertrophy factor, the presence of nuclear clumps and an increase in central nucleation, were 
present in muscles from patients presenting the most severe clinical phenotype (DM1-E2, DM1-
CDM, DM2-PDM, DM2-PROMM). On the contrary, as in control muscles, no histopathological  
changes were observed in muscles from both DM1-E1 and DM2-PS. In order to resolve the 
controversial results on CUGBP1 protein expression in DM2 muscle, we have examined the levels 
of this proteins in biceps brachii muscle samples. Our results indicated that an increase of CUGBP1 
protein level is present in DM muscles as compared to controls even if not statistically significant 
due to the high interindividual variability observed in all groups. However, the increase of protein 
expression appears to be higher in DM1 than in DM2. Moreover, in DM1 the increase was evident 
only in DM1-E2 patients, while DM1-CDM and DM1-E1 showed similar levels to those observed 
in control muscles. On the contrary in DM2 only a slight increase of CUGBP1 expression was 
observable in DM2-PDM and DM2-PROMM but not in DM2-PS. Moreover the CUGBP1 levels in 
DM2-PDM and DM2-PROMM muscles appear to be lower than those observed in DM1-E2 
muscles. Since it has been reported that the increase of CUGBP1 steady state protein level in DM1 
cultured cells or animal models is related to protein hyperphosphorylation, we tested if the increase 
of CUGBP1 expression observed in our DM cohort is related to an increase of its phosphorylation. 
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Western blot analysis of the expression of CUGBP1 phosphorilated in S28 and 2D-GE analysis 
have shown that an hyperphosphorylation of CUGBP1 was present only in DM1-E2 patients which 
also showed the highest levels of CUGBP1 expression. In all the other groups, CUGBP1-p-S28 
levels were similar to those observed in controls. The biomolecular analysis of alternative splicing 
alteration of IR, CLCN1, SERCA1, MBNL1 and CAPZB genes have shown that the frequency of 
abnormal isoforms are significantly increased in every DM1 and DM2 patient as compared to 
controls. Moreover, when considering single phenotypes, DM1-E1 and DM2-PS muscles showed a 
lower frequency of abnormal isoforms than those observed in the other DM1 and DM2 categories, 
confirming that a positive correlation between splicing alteration and clinical phenotype seems to be 
present. On the basis of the observed CUGBP1 increased protein levels in DM1 muscle, particular 
attention should be given to the expression of the CAPZB gene, which encodes for the F actin 
capping protein beta subunit. Indeed CAPZB splicing is dependent only on CUGBP1 and RT-PCR 
analysis showed that DM1-E2 patients exhibit the highest levels of its fetal isoform. Since it’s 
known that elevated concentration of intracellular Ca
2+
 can lead to muscle degeneration and muscle 
atrophy, we have analyzed if there is a correlation between histopathological alterations in DM 
muscles and the expression of pathological isoform of SERCA1 which is one of the main regulators 
of intracellular Ca
2+
 homeostasis in skeletal muscle cells (Jacobs et al., 1990). The results indicated 
that there is a significant correlation between SERCA1 splicing alteration and the atrophy factor in 
DM1 but not in DM2 muscle. The results indicated that the splicing and muscle pathological 
alterations observed are related to the clinical DM1 and DM2 phenotype and that CUGBP1 seems 
to play a role only in DM1, confirming that the molecular pathomechanism of DM is more complex 
than the one actually suggested. In particular the reasons behind skeletal muscle histopathological 
alterations are still unclear. For these reasons, to better understand the molecular mechanisms 
underlying DM2 pathology, we decided to study the progression of the muscular involvement in 
relation to the evolution of skeletal muscle histopathology and biomolecular findings in DM2 
patients. Indeed, we have analyzed at histopathological and biomolecular level the progression of 
the disease over time in 5 different DM2 patients. Our results indicated that a clear worsening in 
muscle histopathology over time was evident in every patient analyzed, where an increase in the 
percentage of type 2 fibres presenting central nucleation, in the number of fast positive nuclear 
clumps and in fibres atrophy were evident. On the contrary, no differences or only a slight increase 
of alteration in alternative splicing of some mRNAs (IR, CLCN1, SERCA1, MBNL1) was 
observable between the two biopsies. Moreover, as mentioned above, since it’s known that elevated 
concentration of intracellular Ca
2+
 can lead to muscle degeneration and muscle atrophy, particularly 
attention should be given to the analysis of SERCA1 alternative splicing. This mRNA was found to 
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be more altered in the second biopsy only in 3 patients but with no correlation with the worsening in 
histopathological phenotype. Finally, since it is known that an alteration in ZNF9/CNBP protein 
expression can lead to a reduction in the rate of global protein synthesis, potentially explaining 
muscle atrophy in DM2, we decided to analyze CNBP protein levels in the two successive DM2 
biopsies. Our results indicated that this protein appear to be reduced in DM2 muscles compared to 
control samples but again no differences were found between the two biopsies. All these data 
suggest that the molecular mechanisms that drive to skeletal muscle histopathological alterations 
and in particular to skeletal muscle atrophy are still unclear and that these features cannot be 
explained only by spliceopathy. 
For all these reasons we decided to analyze DM satellite cells activity in vitro. Satellite cells are 
the muscle precursor cells that provide the potential for both pre and post-natal growth of skeletal 
muscles and for its regeneration following injury (Bischoff et al., 1994; Relaix et al., 2012). Since it 
has been observed that human DM1 myoblasts undergo senescence earlier than control cells, we 
decided to analyze if also DM2 satellite cells derived myoblasts exhibit a premature senescence as 
reported for DM1 (Thornell et al., 2009). The in vitro proliferative capacity of myoblasts obtained 
from skeletal muscle biopsies of 3 DM1 and 4 DM2 patients was compared to that of myoblasts 
obtained from 4 age matched unaffected individuals used as controls. Our results indicated that, 
even if an interindividual variability was evident in both DM1 and DM2 group, the average 
proliferative lifespan of the DM1 and DM2 myoblasts was reduced as compared to that observed in 
control cells. Since it is known that replicative senescence may be caused by progressive telomere 
shortening at each cellular division or by additional pathways such as the p16 stress pathway, we 
decided to anlalyse p16 expression in DM and control myoblasts at early and late stages of 
proliferation and telomeres shortening during in vitro aging. Interestingly our results indicated that 
p16 was overexpressed only in DM1 cells at both early and late stages of proliferation compared to 
controls, while no differences were found in DM2 and control myoblasts at both stages analyzed. 
On the contrary, telomere loss analysis have shown that only myoblasts isolated from DM1 patients 
stopped growing prematurely with telomeres longer than controls. Indeed, DM2 myoblasts stopped 
dividing with a median telomere length lower than controls and DM1 samples and had a clear 
decrease in the amount of telomeric DNA at every cell passage compared to controls. Finally, the 
analysis of myoblasts differentiative capability have shown that senescent cells from both control 
and DM patients were still able to form myotubes, however they appeared to be significantly 
smaller than those formed by the young cells, confirming that premature proliferative growth arrest 
of DM satellite cells might contribute to skeletal muscle atrophy in these patients.  
Finally, to better understand the mechanisms behind skeletal muscle atrophy, we decided to 
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analyze another pathway involved in the regulation of skeletal muscle atrophy and hypertrophy 
which is the insulin/IGF1 pathway. Indeed DMs are characterized by metabolic dysfunctions such 
as insulin resistance, hyperinsulinemia, hypertriglyceridemia, increased fat mass, and a fourfold 
higher risk of developing Diabetes mellitus type 2 (T2DM) (Meola 2000). However in literature 
there are few studies aimed to clearly define the mechanisms underlying insulin resistance in DM. 
Savkur et al. (2001) suggested that splicing alteration of insulin receptor (IR) may play a role in 
peripheral insulin resistance. This splicing alteration leads to a higher expression of the fetal 
isoform A (IR-A, lacking exon 11) than the isoform B (Savkur et al., 2001). Moreover, the 
expression of IR in DM patients is still controversial since both normal and diminished insulin 
receptor (IR) RNA and protein levels have been reported (Savkur et al., 2001; Moxley et al., 1981; 
Morrone et al., 1997; Furling et al., 1999). Thus it cannot be excluded that post receptor signalling 
abnormalities could also contribute to the insulin resistance observed in DM patients and that 
insulin response defects might play a key role in the metabolic manifestations of DM, potentially 
leading to type II diabetes and abnormal muscle protein metabolism (Moxley et al., 1984, 1986). In 
this background, we decided to analyze the molecular mechanisms that induce insulin resistance in 
myotubes at five days of differentiation (T5) derived from myoblasts isolated from muscle biopsies 
of 3 DM1, 3 DM2 and 3 healthy subjects. Alternative splicing analysis of the insulin receptor (IR) 
have shown that at five days of differentiation (T5) both DM and control myotubes express more 
fetal isoform IR-A than the adult one (IR-B), confirming what was previously reported by Cardani 
et al. (2009). However, DM1 and DM2 muscle cells exhibited a lower glucose uptake after 10 nM 
insulin stimulation. Moreover, also the activation of several proteins involved in the insulin pathway 
(p70S6K, AKT, GSK3β) appeared to be lower in DM myotubes than in controls and this alteration 
seems to be more evident in DM2 muscle cells. It is known that the binding of insulin to its receptor 
activates a complex pathway culminating in the translocation of the glucose transporter GLUT4 into 
the plasma membrane. Since the cytoskeleton provides a platform for intracellular transport, we 
decided to investigate if actin and microtubule organization is impaired in DM skeletal muscle cells. 
Fluorescent analysis of actin remodelling in response to insulin stimulation did not show any 
difference between control and DM myotubes. However, microtubule nucleation analyzed by γ-
tubulin staining has shown that DM muscle cells exhibit a defective microtubule reorganization 
after insulin stimulation. This alteration was associated with an increased activation of ERK1/2 and 
of GSK3β. These data indicate that post receptor signalling abnormalities might contribute to DM 
insulin resistance regardless the alteration of IR splicing. 
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5. Conclusions and Future Prospects 
Myotonic dystrophy (DM) is an autosomal dominant multisystemic disorder characterized by a 
variety of multisystemic features including myotonia, muscular dystrophy, cerebral involvement, 
cardiac dysfunctions, cataracts and insulin-resistance (Meola and Moxley, 2004). However DM1 
and DM2  present a number of very dissimilar features making them clearly separate diseases. For 
these reasons in the first part of my PhD we have performed different studies to analyze the 
histopathological and biomolecular features of skeletal muscle biopsies from a cohort of DM1 and 
DM2 patients in relation to different phenotypes. The results of our studies seem indicate that the 
splicing and muscle pathological alterations observed are related to the clinical phenotype. Indeed 
the most severe phenotype of both DM1 and DM2 showed the characteristic myopathic features of 
these diseases, while the less affected patients presented none or minimal muscle histopathological 
alterations. Moreover, as expected, alteration of alternative splicing of IR, CLCN1, MBNL1, 
SERCA1 and CAPZB genes was evident in both DM1 and DM2 muscle biopsies despite the 
clinical phenotype. To better define the molecular pathways which may be involved in disease-
specific manifestations, we have analyzed the role of CUGBP1. Indeed, while it is clear that 
MBNL1 is depleted from nucleoplasm through recruitment into ribonuclear inclusions both in DM1 
and DM2 even when clinical symptoms and muscle alterations are very mild, CUGBP1 
overexpression has been clearly demonstrated in DM1 but not in DM2 muscle biopsies (Mahadevan 
et al., 2006; Jiang et al., 2004; Mankodi et al., 2005; Gates et al., 2011; Cardani et al., 2012). Our 
western blotting analysis of CUGBP1 protein expression confirms that CUGBP1 is overexpressed 
and more phosphorylated in DM1 muscle biopsies. However this increase was evident only in 
DM1-E2 while CUGBP1 protein levels in DM-E1 and DM1–CDM appeared to be similar to those 
observed in healthy controls. It has been suggested that in DM1 CUGBP1 may be responsible for 
muscle wasting since the transgenic mice with skeletal muscle-specific expression of CUGBP1 
reproduces the dystrophic muscle histology characteristic of DM1, while MBNL1 knockout mice 
do not exhibit severe muscle wasting (Kanadia et al., 2003; Ward et al., 2010). In our work we have 
found a clear correlation between CUGBP1 expression and the atrophy factors found in DM1 
muscles. However, when considering the different DM1 clinical phenotypes, DM1-E2 and DM1-
CDM showed the higher values of atrophy factor and the most severe muscle histopathological 
alterations nevertheless CUGBP1 was overexpressed only in DM1-E2 muscles. Contrary to DM1, 
in DM2 muscle biopsies only a slight increase of the CUGBP1 protein levels was observed in 
DM2-PDM and DM2-PROMM but not in DM2-PS. However this increase was not related to an 
increase of protein phosphorylation. In addition our data on DM2 muscle seem to suggest that 
perturbation of CUGBP1 amount are not required to produce histopathological or splicing 
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regulation defects in DM2. Thus, since sequestration of MBNL1 evidently has a central role in 
splicing misregulation in both types of DM, it appears likely that in DM1 CUGBP1 overexpression 
might be an additional pathogenic mechanism not shared by DM2. These results confirm that the 
molecular pathomechanism of DM is more complex than the one actually suggested and in 
particular that the reasons behind skeletal muscle histopathological alterations are still unclear. All 
these results were confirmed by the analysis of the progression of the muscular involvement in 
DM2 patients. The analysis of two successive biopsies of five patients indicated that muscle 
morphological alterations evolve more rapidly over time than the molecular changes. Indeed, even 
if muscle degeneration appears to be more pronounced after a 10-year interval between the two 
successive biopsies, it was already evident after 2 years. This degenerative process may explain the 
worsening of muscle symptoms like weakness and wasting. Interestingly, this worsening of muscle 
symptoms in DM2 patients may be caused by the progressive enlargement of CCTG and by the 
consequent increase of the sequestration of MBNL1 that we observed in the second biopsy of every 
DM2 patient analyzed. Moreover, it has been suggested that a reduction of CNBP levels may play a 
role in DM2 pathology and might explain phenotypic differences between DM1 and DM2 (Chen et 
al., 2007; Huichalaf et al., 2009; Pelletier et al., 2009; Raheem et al., 2010). In this work we have 
observed a reduction of CNBP both at the mRNA and protein level in DM2 muscle, however this 
reduction was not related to a worsening of muscle histology. Finally, the analysis of alternative 
splicing of IR, SERCA1, CLCN1and MBNL1 genes in two successive muscle biopsies did not 
evidence a worsening of alternative splicing alterations even after a 10-year interval between the 
two biopsies. Moreover, since it’s known that elevated concentration of intracellular Ca2+ can lead 
to muscle degeneration and muscle atrophy, particularly attention should be given to the analysis of 
SERCA1 alternative splicing. This mRNA was found to be more altered in the second biopsy only 
in 3 patients but with no correlation with the worsening in histopathological phenotype. All these 
data suggest that the molecular mechanisms that drive to skeletal muscle histopathological 
alterations and in particular to skeletal muscle atrophy are still unclear and that these features 
cannot be explained only by spliceopathy.  
Since many symptoms of adult form of DM1 and DM2, such as muscle weakness and wasting, 
cataracts, and cardiac arrhythmias, are reminiscent to normal aging, we decided to analyze if also 
skeletal muscle atrophy can be linked to a premature aging of skeletal muscle. Supporting this 
thesis, recent data on dystrophic skeletal muscle myonuclei have demonstrated alterations of mRNA 
pathways similar to those observed during aging (Moss and Leblond, 1971; Malatesta et al., 2009; 
2011; 2013). Moreover several studies have shown that in age-related myopathies, such as 
sarcopenia and myotonic dystrophy, the progressive muscle weakness and atrophy are characterized 
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by impaired muscle regeneration due to satellite cells premature senescence that limits their 
proliferative potential (Harper 2001; Bigot et al., 2009; Machida et al., 2006; Verdijk et al., 2007). 
Thornell et al. (2009) have shown that in DM1 muscles the number of satellite cells is increased 
compared to muscles from non-affected individuals; however, DM1 cells do not seem to be able to 
counteract the progressive muscle atrophy due to a reduced proliferative capacity triggered by a 
mechanism of premature growth arrest. To investigate if these alterations are evident also in DM2 
patients, we have analyzed if cultured DM2 myoblasts differ from myoblasts of age-matched DM1 
and normal individuals in terms of cell proliferation, morphology, differentiation and senescence 
during in vitro aging and if alterations in their proliferation potential and differentiation capabilities 
might contribute to some of the clinical and histopathological features observed in DM2 muscles. 
Our results seem indicate that DM1 and DM2 myoblasts are characterized by a premature 
proliferative growth arrest compared to healthy myoblasts suggesting that the in vivo regenerative 
capacity of DM satellite cells might be constitutively impaired. Interestingly, while the p16 pathway 
appeared to be responsible for the premature growth arrest in DM1, our results suggested that this 
mechanism was not responsible for the proliferative arrest observed in DM2 myoblasts (Bigot et al., 
2009). On the contrary, DM2 myoblasts stopped dividing with telomeres shorter than controls 
suggesting that the signaling involved in premature senescence depend on a telomere-driven 
pathway and indicating that CCTG expansion might interfere with the telomere homeostasis in 
DM2 cells. However further analysis are necessary to clarify the mechanism causing an accelerated 
telomere shortening. Critically short telomeres trigger loss of cell viability in tissues, which has 
been related to alteration of tissue function and loss of regeneration tissue capabilities (Decary et 
al., 1997; 2000). This study has shown that CTG and CCTG expansions trigger in vitro a 
mechanism of myoblast premature senescence through two different pathways, which could explain 
the different histological alterations observed between DM1 and DM2 skeletal muscle. Moreover, 
as previously reported, our results indicated that replicative senescence deregulates the myogenic 
programme resulting in impaired myogenesis (Mathieu et al., 2001; Lorenzon et al., 2004; Bigot et 
al., 2009). Indeed, even though the senescent myoblasts are still able to fuse, a significant reduction 
in the fusion index has been observed when compared with young cells. Moreover, the reduction in 
fusion index appear to be more evident in senescent myoblasts obtained from DM1 patients 
indicating that myoblasts deficiency could be responsible of the more severe muscle histopathology 
observed in DM1 compared to DM2. Thus, the histopathological defects observed in DM muscle 
such as fibre atrophy and nuclear clumps, could be due at least in part to the inability of premature 
aged myoblasts to generate myotubes able to produce mature skeletal muscle fibers or to fuse with 
existing fibers and prevent them from atrophy.  
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Finally, to better understand the mechanisms behind skeletal muscle atrophy, we decided to 
analyze another pathway involved in the regulation of skeletal muscle atrophy and hypertrophy 
which is the insulin/IGF1 pathway. Indeed, when insulin binds its receptor, the activated IR tyrosine 
kinase phosphorylates several intracellular substrates, starting a complex cascade of biochemical 
signals that mediate the metabolic or mitogenic effects by the activation of PI3K or Ras pathway 
(Belfiore et al., 2009). The insulin PI3K/Akt pathway shares most of its components with the IGF1 
(insulin-like growth factor 1) pathway intersecting at various levels. For example, insulin can also 
bind the IGF1 receptor and IGF1 can bind to the insulin receptor; furthermore, hybrids between the 
IGF1 and insulin receptors are present in skeletal muscle. It is known that insulin and IGF play an 
important role in skeletal muscle growth, development, differentiation and regeneration. They 
promote the synthesis and inhibit the degradation of muscle specific proteins through two main 
downstream effectors: mTOR, which controls protein synthesis, and FoxO, which controls protein 
degradation via the proteasomal and autophagic/lysosomal systems. Moreover, in absence of insulin 
stimulus, a loss in muscle mass and strength can be observed (Harridge 2003; Schiaffino et al., 
2011; 2013). Progressive muscle wasting and weakness are very characteristic features of both 
DM1 and DM2 but, unlike other forms of muscular dystrophy, they do not result from fiber 
degeneration accompanied by muscle fibrosis. Indeed, several studies have shown that muscle 
atrophy in myotonic dystrophy reflects a selective decrease in muscle protein synthesis suggesting 
that muscle wasting could be a result from a defect in muscle anabolism (Halliday et al., 1985; 
Griggs et al., 1990). Moreover, DMs are characterized by metabolic dysfunctions such as insulin 
resistance, hyperinsulinemia, hypertriglyceridemia, increased fat mass, and a fourfold higher risk of 
developing Diabetes mellitus type 2 (T2DM) (Meola 2000). However, in literature there are few 
studies aimed to clearly define the mechanisms underlying insulin resistance in DM. Savkur et al. 
(2001) suggested that splicing alteration of insulin receptor (IR) may play a role in peripheral 
insulin resistance. This splicing alteration leads to a higher expression of the fetal isoform A (IR-A, 
lacking exon 11) than the isoform B (Savkur et al., 2001). IR-B differs from IR-A by the inclusion 
of exon 11 that leads to a higher insulin signalling capability. However, it cannot be excluded that 
post receptor signalling abnormalities could also contribute to the insulin resistance observed in DM 
patients and that insulin response defects might play a key role in the metabolic manifestations of 
DM, potentially leading to type II diabetes and abnormal muscle protein metabolism (Moxley et al., 
1984; 1986). In this background, we decided to analyze the molecular mechanisms that induce 
insulin resistance in myotubes at five days of differentiation (T5). Alternative splicing analysis of 
the insulin receptor (IR) have shown that at five days of differentiation (T5) both DM and control 
myotubes express more fetal isoform IR-A than the adult one (IR-B). However, DM1 and DM2 
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muscle cells exhibited a lower glucose uptake after 10 nM insulin stimulation. This result is 
consistent with what was previously reported by Furling et al. (2009): these authors have shown 
that in CDM myotubes a dose of 10 nM insulin produced no stimulatory effect on glucose uptake 
and on protein synthesis. Moreover, also the activation of several proteins involved in the insulin 
pathway (p70S6K, AKT, GSK3β) appeared to be lower in DM myotubes than in controls and this 
alteration seems to be more evident in DM2 muscle cells. All these data indicate that post receptor 
signalling abnormalities might contribute to DM insulin resistance regardless the alteration of IR 
splicing. However further investigations will be necessary to understand whether these alterations 
may contribute to the histopathological changes observable in skeletal muscle. The results will lead 
to the identification of novel therapeutic approaches to prevent these features of the disease. Indeed, 
metformin is now considered as the first line drug for insulin resistance diseases, including DM, and 
it increases glucose uptake in muscle through an insulin-indipendent pathway (Kouki et al., 2005). 
In the recent years some important component of many foods like Resveratrol, Betaine and 
Carnitine have found to be insulin mimetic compounds since they activate insulin/IGF1 signalling 
pathway leading to hypertrophic effects of C2C12 murine muscle cells (Montesano et al., 2013; 
2015; Senesi et al., 2013).  Moreover Resveratrol has been shown to act on skeletal muscle 
metabolism and function and recently its influence on alternative splicing of pre-mRNA was 
studied on DM1 fibroblasts where it enhanced the inclusion of exon 11 of the IR gene, providing a 
justification of resveratrol as a leading compound to improve glucose tolerance in DM1 (Takarada 
et al., 2015). For these reasons we intend to study the effects of resveratrol, betaine and carnitine on 
insulin resistance and skeletal muscle atrophy in DM patients as alternative drugs to metformin 
since they are insulin mimetic natural compounds that might have lower side effects.  
In order to investigate the molecular mechanisms that induce insulin resistance in skeletal muscle in 
both DM1 and DM2 patients, we decided to analyze cytoskeleton organization in DM1 and DM2 
muscle cells. Indeed, it is known that the binding of insulin to its receptor activates a complex 
pathway culminating in the translocation of the glucose transporter GLUT4 into the plasma 
membrane and the cytoskeleton provides a scaffold for intracellular transport such as the movement 
of vesicles and organelles. The importance of identifying the molecular mechanisms by which 
cytoskeletal elements contribute to GLUT4 translocation is underscored by recent studies that 
highlight defects in actin dynamics in conditions of insulin resistance (JeBailey et al., 2007; Zaid et 
al, 2008). Our results indicated that in control myotubes there is an insulin-dependent 
reorganization of microtubules that is associated with a translocation of GLUT4 and in the uptake 
of glucose. These results are consistent with what other authors have previously reported. Indeed, 
some studies have shown that microtubule depolymerizing agents such as nocodazole attenuate the 
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insulin-stimulated plasma membrane fusion of GLUT4 (Liu et al., 2013; Fletcher et al., 2000). 
Interestingly, γ-tubulin staining has shown that DM muscle cells exhibit a defective microtubule 
reorganization after insulin stimulation. Moreover, DM myotubes exhibited an increase in basal 
microtubule nucleation as compared to controls. These results seem indicate that DM muscle cells 
have a global alteration in microtubule nucleation and stabilization. This alteration was consistent 
with the observed increased activation of ERK1/2 and GSK3β. Indeed, polymerization and stability 
of microtubules is regulated by a number of microtubule associated proteins (MAPs) and moreover 
ERK and GSK3β have been shown to phosphorylate and regulate the binding activity to 
microtubules of these proteins. ERK1/2 (extracellular signal-regulated kinases) belong to the family 
of MAPK (mitogen-activated protein Kinases) and are strongly activated by growth factors, 
cytokines, osmotic stress, and microtubule disorganization (Lewis et al., 1998). Moreover, once 
activated, they phosphorylate numerous substrates in all cellular compartments, including 
cytoskeletal proteins (Chen et al., 2001). GSK3β is a constitutively active protein kinase whose 
activity is inhibited by phosphorylation upon insulin stimulation. Interestingly, type 2 Diabetes 
(T2D) is strongly associated with a decrease in insulin-stimulated glycogen synthesis along with 
increased GSK3β protein levels in the muscle (Bogardus et al., 1984; Shulman et al., 1990; Kelley 
et al., 1996; Cline et al., 1999). These data indicate that microtubule abnormalities might contribute 
to insulin resistance observed in DM myotubes. However further analysis are necessary to 
understand if an alteration in other cytoskeletal proteins may be involved in the molecular 
mechanism that induce insulin resistance in myotonic dystrophy. Indeed several studies have shown 
that in DM1 and DM2 patients several proteins involved in the cytoskeleton and in vesicle transport 
undergo to an aberrant alternative splicing, supporting the hypothesis that GLUT4 trafficking, 
docking and fusion could be altered in DM muscle cells leading to insulin resistance (Nakamori et 
al., 2013; Perfetti et al., 2014). Moreover, further investigations will be necessary to identify if 
microtubule instability might be related to other clinical features of this disease. 
In conclusion, all these data suggest that the molecular mechanisms behind skeletal muscle 
atrophy in DM patients is more complicated than the one suggested and moreover this feature 
cannot be explained only by spliceopathy. Moreover, even if further investigations are necessary to 
understand how CTG and CCTG expansions lead to an alteration in satellite cells activity and in the 
regulation of the insulin/IGF1 pathway, our analysis have shown that the pathogenetic mechanisms 
in DM1 and DM2 present a number of very dissimilar features that make them clearly separate 
diseases. 
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Part III 
Post insulin receptor signalling abnormalities in myotonic dystrophy skeletal muscle cells 
1. Background and significance of the project 
Myotonic dystrophy (DM) is an autosomal dominant multisystemic disorder characterized by a 
variety of multisystemic features including myotonia, muscular dystrophy, cardiac dysfunctions, 
cerebral involvement, cataracts and insulin-resistance (Mankodi and Thornton, 2002; Meola and 
Moxley, 2004). Myotonic dystrophy type 1 (DM1) is caused by an expanded (CTG)n in the 3’ 
untranslated region of the Dystrophia Myotonic Protein Kinase (DMPK) gene, while DM2 is caused 
by the expansion of a tetranucleotidic repeat (CCTG)n in the intron 1 of the CCHC-type zinc finger, 
nucleic acid-binding protein (CNBP) gene (Brook et al., 1992; Fu et al., 1992; Mahadevan et al., 
1992; Ricker et al., 1994; Liquori et al., 2001). In both forms, the mutant transcripts accumulate in 
nuclear foci altering the function of alternative splicing regulators, CUGBP1 and MBNL1, which 
are necessary for the physiological processing of mRNAs. These alterations lead to aberrant 
alternative splicing of different genes (spliceopathy) that may explain different DM features (Taneja 
et al., 1995; Philips et al., 1998; Michalowski et al., 1999; Mankodi et al., 2001; Timchenko et al., 
2001; Ranum and Day, 2004; Day and Ranum, 2005). DMs are characterized by metabolic 
dysfunctions such as insulin resistance, hyperinsulinemia, hypertriglyceridemia, increased fat mass, 
and a fourfold higher risk of developing Diabetes Mellitus type 2 (T2DM) (Meola 2000). However, 
in literature there are few studies aimed to clearly define the mechanisms underlying insulin 
resistance in DM. Savkur et al. (2001) suggested that splicing alteration of insulin receptor (IR) may 
play a role in peripheral insulin resistance. This splicing alteration leads to a higher expression of 
the fetal isoform A (IR-A, lacking exon 11) than the isoform B (Savkur et al., 2001). IR-B differs 
from IR-A by the inclusion of exon 11 that leads to a higher insulin signalling capability, potentially 
explaining DM insulin resistance (Savkur et al., 2001; 2004; Cardani et al., 2009; Loro et al., 2010). 
However, it cannot be excluded that post receptor signalling abnormalities could also contribute to 
the insulin resistance observed in DM patients and that insulin response defects might play a key 
role in the metabolic manifestations of DM, potentially leading to type 2 diabetes and abnormal 
muscle protein metabolism (Moxley et al., 1984; 1986). 
For all these reasons, the aim of this project was to investigate the molecular mechanisms that 
induce insulin resistance in skeletal muscle cells obtained from both DM1 and DM2 patients. 
 
2. Results and Discussion 
This work has been performed on primary cultures of satellite-cell-derived myoblasts from 
biceps brachii biopsies of 3 adult DM1, 3 DM2 and 3 age-matched control patients. As reported by 
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Cardani et al. (2009), human muscle biopsy has been trimmed of blood vessels, fat and connective 
tissues and rinsed in phosphate-buffered saline, pH 7.4. The trimmed biopsies has been minced into 
pieces of 1 mm
3
, dissociated with trypsin for 45 min at 37°C and isolated muscle cells have been 
plated in proliferative medium. As reported in figure 1, myoblasts obtained from satellite cells have 
been grown in proliferative medium without insulin until 80% confluence (T0), then the 
proliferative medium has been replaced with a differentiative medium containing a lower 
concentration of serum (15% FBS in proliferative medium vs 7% FBS in differentiative medium) to 
allow the fusion and differentiation of myoblasts into myotubes. After 5 days of differentiation (T5) 
human myotubes have been starved from serum overnight and then treated with insulin to study the 
activation of the insulin pathway in DM muscle cells. 
 
 
Figure 1: Schematic representation of the protocol used for in vitro study of the insulin 
pathway. 
 
2.1 Insulin receptor splicing and expression 
In this work we have analyzed insulin receptor (IR) expression and its alternative splicing in 5 
days differentiated myotubes of healthy (control), DM1 and DM2 subjects (figure 2). The insulin 
receptor is a glycoprotein comprised of two α-subunits and two β-subunits linked by disulfide bonds 
(Whitehead et al., 2000). The binding of insulin to the α-subunit causes phosphorylation of the β-
subunit on multiple tyrosine residues. In DM the nuclear accumulation of CUG/CCUG-containing 
RNA alters the levels of splicing factors which are required for alternative splicing of IR leading to 
an increase in IR-A:IR-B ratio in skeletal muscle biopsies and muscle cells of DM patients (Savkur 
et al., 2001; 2004; Cardani et al., 2009; Loro et al., 2010). However, the expression of insulin 
receptor (IR) in DM patients is still controversial since both normal and diminished RNA and 
protein levels have been reported (Savkur et al., 2001; Moxley et al., 1981; Morrone et al., 1997; 
Furling et al., 1999). Alternative splicing of the insulin receptor has been analyzed by RT-PCR and 
our results have shown that at five days of differentiation (T5) both control and DM myotubes 
express more fetal than adult IR isoform (56,8% IR-A/Total expression in CTR vs 59,1% IR-
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A/Total expression in DM1 vs 56,6% IR-A/Total expression in DM2) (figure 2A, 2B). These results 
are consistent with those previously reported by Cardani et al. (2009) on IR alternative splicing 
regulation during human control myogenesis. Indeed, these authors reported that in control 
myoblasts (T0) and myotubes at early stages of differentiation (T4) the alternative splicing of the IR 
leads to a higher expression of the fetal isoform similar to what observed in DM muscle cells. 
Instead, at late stages of differentiation (T10), control but not DM myotubes express higher levels 
of adult IR-B isoform. QRT-PCR analysis have shown that there are no statistically significant 
differences in IR gene expression between CTR, DM1 and DM2 myotubes (figure 2C).  
 
 
Figure 2: Insulin receptor (IR) alternative splicing and expression in 5 days (T5) differentiated 
human myotubes. A) Splicing products obtained by RT-PCR amplification of RNA isolated from 
myotubes obtained from control, DM1 and DM2 patients. B) Densitometric analysis measuring the 
fraction of aberrant gene isoform IR-A in control, DM1 and DM2 myotubes. Bars represent 
standard deviation. C) IR mRNA expression in T5 myotubes from control, DM1 and DM2 patients. 
The relative amount of IR transcripts has been determined using the GAPDH as endogenous control 
genes. Bars represent standard deviation. 
 
2.2 Glucose uptake 
Resistance to insulin action in human myotubes was first investigated at glucose uptake level. 
Glucose uptake is an important biological process for studying glucose metabolism. Among many 
different methods available for measuring glucose uptake, 2-deoxyglucose (2-DG) has been widely 
used because of its structural similarity to glucose. As with glucose, 2-DG can be taken up by 
glucose transporters and metabolized to 2-DG-6-phosphate (2-DG6P). 2-DG6P, however, cannot be 
further metabolized, and thus accumulates in the cells. The accumulated 2-DG6P is directly 
proportional to 2-DG (or glucose) uptake by cells. In BioVision’s glucose uptake colorimetric assay 
kit, the 2-DG6P is oxidized to generate NADPH, which can be determined by an enzymatic 
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recycling amplification reaction. Figure 3A shows the insulin dose-response curve of 2-DG uptake 
in 5 days differentiated myotubes derived from 2 control subjects. Our results have confirmed that 
human skeletal muscle cultures provide a powerful tool for the investigation of the biochemical and 
genetic basis of peripheral insulin resistance, since glucose uptake remain responsive to insulin in 
cultured muscle cells from control subjects. In our control samples, each insulin concentration used 
induced an increase in glucose uptake. However, this increase resulted higher with 100 nM and 10 
nM insulin (1,5 fold change with 1 μM vs 3,7 fold change with 100 nM vs 4,9 fold change with 10 
nM). Since control myotubes exhibited the maximal stimulation at 10 nM insulin, we decided to 
perform the analysis of insulin resistance in DM muscle cells at this insulin concentration. The 
results of the glucose uptake assay on DM1 and DM2 myotubes have shown that DM muscle cells 
exhibit a lower glucose uptake after 10 nM insulin stimulation as compared to control cells. 
Interestingly, in DM myotubes the levels of glucose uptake after insulin stimulation were similar to 
those observed in myotubes before insulin stimulation (basal level), suggesting that the insulin 
pathway could be altered in DM muscle cells (figure 3B). These results are consistent with the 
results observed by Furling et al. (1999) in CDM (the congenital phenotype of myotonic dystrophy 
type 1) myotubes, where the treatment of CDM muscle cells with 10 nM insulin had no significant 
effect on glucose uptake. 
 
 
Figure 3: A dose-response histogram of insulin action on 2-deoxyglucose uptake in human 
myotubes. Cells were depleted of serum in DMEM containing 5,5 mM glucose (low glucose) for 16 
h and incubated in the absence or presence of insulin for 40 min at 37°C, and then 2-deoxyglucose 
uptake was measured using a colorimetric assay kit from Bio Vision. A) 2-DG uptake performed in 
control myotubes (T5) in the absence or presence of increasing concentration of insulin (1 μM, 100 
nM and 10 nM). B) 2-DG uptake performed in control, DM1 and DM2 myotubes (T5) in the 
absence or presence of 10 nM insulin. Bars represent standard deviation. 
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2.3 Insulin signaling activation 
When insulin binds its receptor, the activated IR tyrosine kinase phosphorylates several 
intracellular substrates, starting a very complex cascade of biochemical signals with two major 
signalling pathways: one mediated by the activation of PI3K and the other by the activation of RAS 
(Belfiore et al., 2009). To investigate the response to insulin stimulation, 5 days differentiated 
myotubes (T5) have been treated from 0 to 30 minutes with 10 nM insulin as described in figure 1 
and the activation of several proteins involved in PI3K pathway has been analyzed by western blot. 
As shown in figure 4, western blot analysis confirmed the glucose uptake results. Indeed, the 
analysis of AKT, p70 and GSK3β activation has shown that control myotubes at five days of 
differentiation are responsive to 10 nM insulin despite the higher expression of the fetal isoform of 
the insulin receptor. On the contrary, DM1 and DM2 myotubes exhibited a lower regulation of 
these proteins compared to controls (figure 4, 2). In particular, AKT phosphorylation in control 
myotubes increased after 5 minutes of insulin stimulation. This increase was lower in DM 
myotubes. However, while in DM1 muscle cells an increase in AKT activation was still evident at 5 
minutes of insulin stimulation, in DM2 cells insulin did not seem to have a positive effect on AKT 
activation. In control myotubes was clearly evident also an activation of p70, with a maximum 
phosphorylation at 15 minutes of insulin stimulation. Again, this increase was less evident in DM1 
muscle cells, while in DM2 myotubes the activation of this protein did not change during insulin 
stimulation. Finally, while in control myotubes insulin induced a down-regulation of the active 
GSK3β isoform (Y216-GSK3β), DM myotubes showed an increase in the expression of this 
GSK3β isoform during the 30 minutes of stimulation. These results on the insulin signaling 
activation clearly demonstrated that post receptor signaling abnormalities might contribute to DM 
insulin resistance regardless the alteration of IR splicing. 
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Figure 4: Insulin signaling activation. A) Western blot analysis of the activation of some proteins 
involved in the insulin pathway. Myotubes at 5 days of differentiation were depleted of serum in 
DMEM containing 5,5 mM glucose (low glucose) for 16 h and incubated in the absence or presence 
of 10 nM insulin for 0 to 30 min at 37°C. B) Activation of AKT in control, DM1 and DM2 
myotubes. C) Activation of p70S6K in control, DM1 and DM2 myotubes. D) Activation of GSK3β 
in control, DM1 and DM2 myotubes. Bars represent standard deviation. 
 
 
 
2.4 Cytoskeleton organization 
In order to investigate the molecular mechanisms that induce insulin resistance in skeletal 
muscle in both DM1 and DM2 patients, we decided to analyze cytoskeleton organization in DM1 
and DM2 muscle cells. Indeed, it is known that the binding of insulin to its receptor activates a 
complex pathway culminating in the translocation of the glucose transporter GLUT4 into the 
plasma membrane and the cytoskeleton provides a scaffold for intracellular transport such as the 
movement of vesicles and organelles. The importance of identifying the molecular mechanisms by 
which cytoskeletal elements contribute to GLUT4 translocation is underscored by recent studies 
that highlight defects in actin dynamics in conditions of insulin resistance (JeBailey et al., 2007; 
Zaid et al, 2008). However, there are few studies regarding cytoskeleton reorganization in response 
to insulin and no studies have been performed on human muscle cells. Since it has been observed 
that actin filaments seems to play a role in GLUT4 translocation in L6 myotubes, we firstly 
analyzed actin remodelling in control and DM myotubes. Phalloidin staining during 60 minutes of 
insulin stimulation did not show any difference in control and DM myotubes. Indeed, remodelling 
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in actin cytoskeleton was present in few myotubes and with no direct correlation with insulin 
stimulation (figure 5). These results did not confirm those reported by other authors for actin 
dynamics in L6 and C2C12 myotubes, where actin ruffles formation was evident upon insulin 
stimulation. However, these differences could be explained by the different cell line and/or by the 
different insulin concentration used (Khayat et al., 2000; Bisht and Dey, 2008; Liu et al., 2013). 
We then decided to analyze if a reorganization in microtubules network could play a role in GLUT4 
translocation after insulin stimulation, since microtubules serve as tracks for directed intracellular 
transport. Microtubules are hollow cylindrical polymers that are assembled from heterodimers 
composed of α- and β-tubulin. Confocal analysis of α-tubulin immunostaining at 0, 5, 15, 30 and 60 
minutes of 10 nM insulin stimulation did not show any remodelling of microtubule network both in 
control and DM myotubes (data not shown). However, it is well known that microtubule network is 
involved in insulin-stimulated plasma membrane translocation of GLUT4 (Fletcher et al., 2000; Liu 
et al., 2013). Therefore, our fluorescence analysis of α-tubulin could have not allowed us to observe 
the expected microtubule remodelling. For these reasons, we decided to analyze another member of 
the tubulin family, γ-tubulin, which is involved in the formation of new microtubule polymers 
(“nucleation”) that could occur in myotubes during insulin stimulation. The analysis of γ-tubulin 
staining in control myotubes (T5) has shown that there is an insulin dependent increase in 
microtubule nucleation that reach its highest level after 15 minutes of 10 nM insulin stimulation 
(figure 6, 7A). In particular, this modulation in microtubule nucleation was associated with an 
insulin-dependent increase in the percentage of cytoplasmic γ-tubulin spots that was evident in 
every myotube analyzed (15% of cytoplasmic spots at 0 minutes vs 37% of cytoplasmic spots at 5 
minutes vs 12% of cytoplasmic spots at 60 minutes) (figure 6, 7B). The results obtained in control 
myotubes confirmed the hypothesis that microtubule network is involved in insulin action in human 
muscle cells as well as in other muscle cell lines (Fletcher et al., 2000; Liu et al., 2013). 
Interestingly, γ-tubulin staining has shown that DM muscle cells exhibit a defective microtubule 
reorganization after insulin stimulation. Indeed, the number of γ-tubulin spots per myotubes did not 
increase during 60 minutes of stimulation in DM muscle cells, where on the contrary the number of 
cytoplasmic spots decreased during insulin stimulation (figure 6,7A,7B). Moreover, DM myotubes 
exhibit a 2 fold increase in microtubule nucleation before insulin stimulation as compared to 
controls. These results were confirmed by western blot, were control myotubes showed a 3 fold 
increase in γ-tubulin expression during 30 minutes of insulin stimulation, while on the contrary 
DM1 and DM2 cells exhibited a decrease in its expression (figure 7C, 7D). Taken together these 
results seem indicate that DM muscle cells have a global alteration in microtubule nucleation and 
stabilization. This alteration is consistent with the observed increased activation of ERK1/2 and 
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GSK3β (figure 4D, 7C, 7E, 7F). Indeed, polymerization and stability of microtubules is regulated 
by a number of microtubule associated proteins (MAPs) and moreover ERK and GSK3β have been 
shown to phosphorylate and regulate the binding activity to microtubules of these proteins. ERK1/2 
(extracellular signal-regulated kinases) belong to the family of MAPK (mitogen-activated protein 
Kinases) and are strongly activated by growth factors, cytokines, osmotic stress, and microtubule 
disorganization (Lewis et al., 1998). Moreover, once activated, they phosphorylate numerous 
substrates in all cellular compartments, including cytoskeletal proteins (Chen et al., 2001). GSK3β 
is a constitutively active protein kinase whose activity is inhibited by phosphorylation upon insulin 
stimulation. Interestingly, type 2 Diabetes (T2D) is strongly associated with a decrease in insulin-
stimulated glycogen synthesis along with increased GSK3β protein levels in the muscle (Bogardus 
et al., 1984; Shulman et al., 1990; Kelley et al., 1996; Cline et al., 1999). 
These data indicated that microtubule abnormalities might contribute to insulin resistance observed 
in DM myotubes. However, further analysis are necessary to understand if an alteration in other 
cytoskeletal proteins may be involved in the molecular mechanism that induce insulin resistance in 
myotonic dystrophy.  
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Figure 5: Actin dynamics during insulin stimulation. Myotubes (T5) were depleted of serum in 
DMEM containing 5,5 mM glucose (low glucose) for 16 h, incubated in the absence or presence of 
10 nM insulin for 0 to 60 min at 37°C and then fixed, permeabilized and stained for actin 
(phalloidin, red) and for nuclei (DAPI, blu). The images are representative of actin remodelling in 
control muscle cells. Scale bar 50 μM. 
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 Figure 6: Microtubule nucleation during insulin stimulation. Myotubes (T5) were depleted 
of serum in DMEM containing 5,5 mM glucose (low glucose) for 16 h, incubated in the absence or 
presence of 10 nM insulin for 0 to 60 min at 37°C and then fixed, permeabilized and double stained 
for γ tubulin (red, enlargements), fast myosin (green) and for nuclei (DAPI, blu). The images are 
representative of microtubules nucleation in control (left panel), DM1 (central panel) and DM2 
(right panel) muscle cells after 0, 15 and 60 minutes of 10 nM insulin stimulation. Scale bar 200 
μM. 
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Figure 7: Involvement in microtubule network in insulin signaling. A) Number of γ-tubulin 
spots/myotubes. Number of γ-tubulin spots counted in 5 myotubes per time point in control, DM1 
and DM2 coltures. B) Percentage of cytosolic γ-tubulin spots counted in 5 myotubes per time point 
in control, DM1 and DM2 cultures. C) Western blot analysis of the activation ERK1/2 and of the 
expression of γ-tubulin in control, DM1 and DM2 myotubes. D) Expression of γ-tubulin during 30 
minutes of 10 nM insulin stimulation in control, DM1 and DM2 myotubes. E-F) Activation of 
ERK1 and ERK2 during 30 minutes of 10 nM insulin stimulation in control, DM1 and DM2 
myotubes. Bars represent standard deviation. 
 
 
2.4 GLUT4 translocation 
In skeletal muscle, stimulation by insulin results in a significant increase in glucose uptake, 
which is mediated by the glucose transporter GLUT4, one member in a family of six glucose 
transporter proteins (Bell et al., 1993). Subcellular fraction analysis of both adipose cell and skeletal 
muscle cells has shown that upon insulin stimulation, GLUT4 appears to translocate from an 
intracellular storage compartment to the plasma membrane (Birnbaum 1992; Holman and Cushman, 
1994). Confocal analysis of 5 days differentiated myotubes (T5) immunostained for GLUT4 has 
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shown that in control cells, at basal level, the punctinate staining of GLUT4 was mainly localized in 
the perinuclear region (red arrows, figure 8). Moreover, additional punctinate staining was evident 
along the axes of control myotubes. These evidences are consistent with what other authors reported 
in C2C12 muscle cells (Ralston and Ploug, 1996). After 15 minutes of insulin stimulation, a slight 
decrease in perinuclear staining associated with the formation of additional cytoplasmic aggregates 
was evident in every control myotube analyzed (yellow arrows, figure 8). Finally, after 30 minutes 
of 10 nM insulin stimulation, GLUT4 appeared to be uniformly expressed in sarcoplasm of control 
muscle cells. These changes in GLUT4 localization at different time points of insulin stimulation 
seemed to indicate that in control myotubes insulin induced a translocation of GLUT4-storage 
vesicles. On the contrary, in both DM1 and DM2 differentiated myotubes, this movement of 
GLUT4 vesicles was not clearly evident. Indeed, in DM1 cells GLUT4 appeared to be uniformly 
express in the sarcoplasm of myotubes at every time point analyzed (figure 8). Interestingly, DM2 
myotubes showed an evident perinuclear staining at basal level as observed in controls. However, 
the formation of cytoplasmic aggregates was already evident in myotubes not stimulated with 
insulin (yellow arrows). On the contrary after 15 and 30 minutes of insulin stimulation GLUT4 
localization appeared to be uniformly expressed in DM2 cells. These results seemed to indicate that 
the translocation of GLUT4-storage vesicles is impaired in DM1 and DM2 myotubes and these 
alterations are consistent with the global alteration in microtubule nucleation observed in these 
cells. However, our analysis did not allow us to detect the plasma membrane GLUT4 localization 
either in control and in DM myotubes at the time points of insulin stimulation considered. For this 
reason, we are currently analyzing the subcellular distribution of GLUT4 by western blot after 
subcellular fractionating as previously reported by Yonemitsu et al. (2001). The results will finally 
let us understand if a defect in the translocation of GLUT4 from the perinuclear region to the 
plasma membrane could be the reason behind the impaired increase in glucose uptake observed in 
DM myotubes (figure 3). Moreover, in DM1 cells immunofluorescence analysis have shown an 
evident nuclear staining of GLUT4 that is less evident in control and DM2 samples. The nuclear 
localization of GLUT4 has never been investigated by others, and currently we are performing 
nuclear and cytoplasmic protein separation to analyze the nuclear expression of this protein in 
control, DM1 and DM2 myotubes. 
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Figure 8: Immunofluorescence localization of GLUT4 in 5 days differentiated control, DM1 and 
DM2 myotubes. Myotubes (T5) were depleted of serum in DMEM containing 5,5 mM glucose (low 
glucose) for 16 h and incubated in the absence or presence of 10 nM insulin for 0 to 60 min at 37°C, 
and then fixed, permeabilized and stained for GLUT4 (green) and for nuclei (DAPI, blu). The 
images are representative of GLUT4 translocation in control (left panel), DM1 (central panel) and 
DM2 (right panel) muscle cells after 0, 15 and 30 minutes of 10 nM insulin stimulation. Arrows 
indicate the presence of perinuclear staining (yellow arrows) and of cyoplasmic aggregates (red 
arrows). Scale bar 20 μM. 
 
 
 
3. Conclusions and future prospects 
DMs are characterized by metabolic dysfunctions such as insulin resistance, hyperinsulinemia, 
hypertriglyceridemia, increased fat mass, and a fourfold higher risk of developing Diabetes Mellitus 
type 2 (T2DM) (Meola 2000). In literature there are few studies aimed to clearly define the 
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mechanisms underlying insulin resistance in DM. Savkur et al. (2001) suggested that splicing 
alteration of insulin receptor (IR) may play a role in peripheral insulin resistance. This splicing 
alteration leads to a higher expression of the fetal isoform A (IR-A, lacking exon 11) than the 
isoform B (Savkur et al., 2001). IR-B differs from IR-A by the inclusion of exon 11 that leads to a 
higher insulin signalling capability. This study has been the first one that elucidated the molecular 
mechanisms that induce insulin resistance in DM myotubes. In particular, our results indicated that 
post receptor signalling abnormalities might contribute to DM insulin resistance regardless the 
alteration of IR splicing. However, further investigations will be necessary to understand whether 
these alterations may contribute to the histopathological changes observable in skeletal muscle. The 
results will lead to the identification of novel therapeutic approaches to prevent these features of the 
disease. Metformin is now considered the first line drug for insulin resistance diseases, including 
DM, and it increases glucose uptake in muscle through an insulin-indipendent pathway (Kouki et 
al., 2005). In the recent years, some important component of many foods like Resveratrol, Betaine 
and Carnitine have found to be insulin mimetic compounds since they activate insulin/IGF1 
signalling pathway leading to hypertrophic effects of C2C12 murine muscle cells (Montesano et al., 
2013; 2015; Senesi et al., 2013). Moreover, Resveratrol has been shown to act on skeletal muscle 
metabolism and function and recently it has been reported to influence alternative splicing of pre-
mRNA in DM1 fibroblasts where it enhanced the inclusion of exon 11 of the IR gene, providing a 
justification of resveratrol as a leading compound to improve glucose tolerance in DM1 (Takarada 
et al., 2015). For these reasons it could be interesting to study the effects of resveratrol, betaine and 
carnitine on insulin resistance and skeletal muscle atrophy in DM patients as alternative drugs to 
metformin since they are natural insulin mimetic compounds that might have lower side effects. 
In conclusion, developing therapies for the prevention and treatment of insulin resistance 
condition and muscle atrophy process will enhance the quality of life of patients affected by 
myotonic dystrophies. 
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